• Merck’s adjusted EBITDA pre rose to €1.68 billion in Q3 2026 from a year earlier.
• Net sales climbed 6% year over year to €5.63 billion.
• The group agreed to acquire Silence Therapeutics and divest its CDMO business to Lonza.
• Raised FY26 guidance targets net sales of €21.5 billion–€21.9 billion and adjusted EBITDA pre of €6.2 billion–€6.4 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief on November 12, 2026, and is solely responsible for the information contained therein.